An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. or A drug being studied in the treatment of acute leukemias and some other types of cancer. It binds to a protein that is present on the surface of some types of cancer cells and stops them from dividing. Lestaurtinib is a type of receptor tyrosine kinase inhibitor and a type of indolocarbazole alkaloid. Also called CEP-701.